Live data — every record is aggregated from real public sources. VialGrade never sells; it links out to the vendor.
VialGrade
All compounds
GLP-1 / metabolic
Live data

Retatrutide

Weight & metabolic

A triple-agonist (GIP/GLP-1/glucagon) — the newest and most-discussed weight-research compound.

LY3437943Triple GGGG tri-agonist

Get told when a price moves or a lab test changes.

Observed median price

$170

Δ —
Every observation
DateObserved
$179.00
$190.13
$124.99
$64.99
$64.99
$149.99
$149.99
$149.99
$149.99
$300.00
$159.99
$300.00
$300.00
$149.99
$149.99

Not enough listings with 30 days of checks to summarise a change — 0 of 15 qualify so far.

15

Active listings

95 · 99.7%

Independent lab tests

$65–$469

Observed price range

4

Known aliases

Read from the certificate, not re-measured by VialGrade. Purity is not a grade. Purity vs grade

Understand this compound

What is Retatrutide?

In clinical trials

The next-generation weight-loss candidate: it works on three metabolic hormone systems at once — one more than tirzepatide — with striking trial results but no approval yet.

Weight & metabolic
⚠

Good to know: Trial results are promising but it is not an approved drug, so any obtained material is unregulated and unverified; GI tolerability issues are common in trials.

How does Retatrutide work?

The science

A triple agonist at GLP-1, GIP, and glucagon receptors; combines incretin-driven appetite suppression with glucagon-receptor-mediated increases in energy expenditure and fat oxidation.

Mechanism of action from published research — how the molecule behaves, not a claim about any product or any human-use effect.

What is Retatrutide researched for?

Studied for obesity and weight loss, type-2 diabetes, and weight-related knee osteoarthritis.

  • Weight & metabolicStudied in weight, appetite, blood-sugar, and fat-metabolism research.
How far has the research gone?

In clinical trials; Phase 3 (TRIUMPH program) reporting strong weight-loss results, but not yet FDA-approved as of 2026.

Where the science stands — an approved drug is not the same as the research-grade material a vendor sells, which is unregulated regardless.

What should I check before buying?
  • Independent purity. Look for a third-party COA (Janoshik or MZ) showing a measured purity — not just a number the vendor typed.
  • Batch match. The strongest evidence is a certificate for the exact batch you’ll receive, attributed to this vendor — check the cross-verification on the listing.
  • Vendor reputation. See how the vendor is talked about in the community before trusting a new name.

Research context only — VialGrade never gives dosing, medical, or human-use guidance.

Current market

The Retatrutide market

Every Retatrutide listing we track — 15 in all. The standout picks first where the evidence supports them, then the full table, ranked by what a milligram really costs wherever the vendor published a strength we can read.

Open full market

Compare by real cost

Every Retatrutide listing, cheapest per mg first

Sticker prices hide the size, so listings are ranked by what a milligram actually costs — with independently tested purity where it exists. All 15 are here: the last 3 are listings whose vendor never published a strength we can read, so they have no per-mg figure to sort on.

#VendorSizePricePer mgTested purityReal $/active mg
1Bluum Peptides60mg total$469$7.82/mg—$7.84/mgbest valueView
2Bluum Peptides30mg total$279$9.30/mg—$9.33/mgView
3Bluum Peptides20mg total$199$9.95/mg—$9.98/mgView
4Umbrella Labs20mg total20 Milligrams each$200$10.00/mg—$10.0/mgView
5Bluum Peptides15mg total$159$10.6/mg—$10.6/mgView
6Umbrella Labs15mg total15 Milligrams each$170$11.3/mg—$11.4/mgView
7Bluum Peptides10mg total$125$12.5/mg—$12.5/mgView
8Umbrella Labs10mg total10 Milligrams each$150$15.0/mg—$15.0/mgView
9PurerawzUnavailable8mg total$152$19.0/mg—$19.1/mgView
10PurerawzUnavailable10mg total$190$19.0/mg—$19.1/mgView

Open the full Retatrutide market

Real $/active mg divides the price-per-mg by the measured purity — the honest cost of the actual peptide, so a 90%-pure vial isn’t compared as if it were 99%. Too cheap? flags a listing far below the market rate — often underdosing or a fake, not a deal. The crown marks the cheapest non-outlier; best value marks the lowest real cost per active mg. A vendor shown as Unavailable or Low stock is priced here but not currently buyable.

Independent testing

Retatrutide — independent lab tests

Real, publicly verifiable third-party tests. Purity is read from the certificate itself. A test reflects one lab’s result for one submitted batch — not a guarantee that every vial matches.

How does this data get here?

Every record below is a real certificate of analysis, gathered two ways: from the public verification feeds that independent labs (like Janoshik) publish, and from the certificates vendors post on their own product pages. We open each certificate document and read the measured purity, content, batch, and date directly off it — a scraper can’t read a number printed inside an image, so this is done by machine vision, then recorded here with a link back to the original.

Nothing here is typed in by a vendor or invented by us. Where a certificate is missing, we say so rather than filling the gap.

We re-check the lab feed, too. A “still listed” tag means the certificate is currently public in Janoshik’s database — we re-verify against the live feed and stamp the date. If a cert is later pulled, the tag flips. It’s a freshness check on the same source, not a second independent opinion.

What a certificate does & doesn’t prove

Three different questions. Purity (“how clean?”), identity (“is it the right molecule?”, a mass-spec test), and content (“did I get the labeled mg?”) are separate. A vial can be 99% pure and still be the wrong peptide, or the right peptide underdosed. We flag the measured dose against the label above; underdosing is the most common real fraud.

Who submitted the sample matters. Most of these are vendor-submitted — the seller chose which vial to send, so one good certificate doesn’t prove every batch is the same. The gold standard is a blind test, where a buyer sends a vial they bought as a normal customer. Same label doesn’t prove same product; same batch number doesn’t prove same batch.

20

blind tests

99.9%

highest tested purity

CertificateManufacturerBatchPurityContent / doseLab
https://www.mjtpeptides.com/ Blind—99.94%33.89/30mg · fullJanoshik Analytical Still listed Verify
www.qhpeptides.com Blind699.88%60.92/60mg · fullJanoshik Analytical Still listed Verify
Aura Blind—99.86%45.34/40mg · fullJanoshik Analytical Still listed Verify
OUROPEPTIDES.com BlindRT3099.86%34.13/30mg · fullJanoshik Analytical Still listed Verify
https://crystalpeptides.eu/ BlindRT3026CP99.85%31.81 mgJanoshik Analytical Still listed Verify
https://www.htraresearch.cn Blind—99.80%42.72/40mg · fullJanoshik Analytical Still listed Verify
www.HSpeptides.com Blind—99.80%32.89/30mg · fullJanoshik Analytical Still listed Verify
ktswpeptide.com Blind89 9699.77%9.74 mgJanoshik Analytical Verify

Tested batches

Batch test records for Retatrutide

The full test history for one batch — who picked the sample, who tested it, and what came back. It describes the vials that were tested, never every vial they sold.

All batch records

What the research says

Scientific evidence & regulatory status

What the published literature actually shows about Retatrutide — separate from any vendor’s marketing. Each finding links to its paper. This is education, not medical or dosing advice.

Regulatory status

No FDA-approved drug

Investigational; NOT FDA-approved (a triple GLP-1/GIP/glucagon receptor agonist in Phase 3 development)

Honest overall read

Early human data (a single Phase 2 RCT) show very large weight loss, but retatrutide is experimental, unapproved, and lacks long-term safety and cardiovascular-outcome evidence; any product sold as 'retatrutide' outside a trial is not FDA-sanctioned.

Human RCTTriple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023.

In a 48-week Phase 2 RCT of 338 adults with obesity, retatrutide produced a mean body-weight reduction of about -24.2% at the highest (12 mg) dose versus -2.1% with placebo.

Adverse events were dose-dependent and predominantly GI; dose-dependent heart-rate increases were seen, and as a Phase 2 study it does not establish long-term safety.

read the source

Commonly researched together

Often stacked with Retatrutide

Compounds the research community frequently discusses alongside Retatrutide. Not a protocol or a recommendation — a starting point for what to read about next.

US legal status

Investigational drug — not approved, under FDA scrutiny

This is an investigational triple-agonist still in clinical trials. It has no FDA approval for any use, is not a supplement, and the FDA is actively watching the GLP-1-class “research” market. Sold research-use-only; marketing or using it as a drug is not lawful.

Read the full US law →

General information, not legal or medical advice. VialGrade sells nothing and encourages no human use.

Research notes aren’t product proof

Research summaries describe published literature and market data only. They do not establish the identity, quality, safety, or legal status of any listed physical product.